PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30933843-6	2019	On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha.	Ambroxol	19-27	tumor necrosis factor	Mus musculus	170-179	
26881857-7	2016	Four days of daily inhalation of ambroxol at 3.75 or 7.5mg/ml for 20 min suppressed the accumulation of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) and lung tissues, and inhibited increases in the mRNA and protein levels of tumor necrosis factor (TNF)-alpha, CCL-2 and KC, but not interleukin (IL)-1beta in the CS-exposed mice.	Ambroxol	33-41	tumor necrosis factor	Mus musculus	251-284	
26881857-11	2016	Using cultured lung epithelial cells, we demonstrated that pretreatment with ambroxol at 2 or 20 muM inhibited the CSE-induced up-regulation of MUC5AC, TNF-alpha, IL-1beta mRNA levels, which was through inhibiting Erk signaling pathway.	Ambroxol	77-85	tumor necrosis factor	Mus musculus	152-161	
30895504-11	2019	Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha) level, reduction of total glutathione (GSH) that induced by CYP.	Ambroxol	18-21	tumor necrosis factor	Mus musculus	75-102	
30895504-11	2019	Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha) level, reduction of total glutathione (GSH) that induced by CYP.	Ambroxol	18-21	tumor necrosis factor	Mus musculus	104-113	
14504727-8	2004	Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p<0.05).	Ambroxol	87-95	tumor necrosis factor	Mus musculus	31-40